Aayoung Hong

发表

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.

Zhentao Yang, A. Ribas, D. Solit, 2021, Cancer cell.

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

J. Larkin, J. Sosman, A. Ribas, 2015, Cancer cell.

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Antoni Ribas, Kimberly B. Dahlman, Hubing Shi, 2015, Cell.

Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma

Zhentao Yang, R. Lo, S. Dubinett, 2021, Cell reports. Medicine.

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Antoni Ribas, Hubing Shi, Richard A Scolyer, 2014, Cancer discovery.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Antoni Ribas, Hubing Shi, Mark C Kelley, 2014, Cancer discovery.

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

T. Graeber, A. Ribas, Hubing Shi, 2016, Cell Discovery.

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity.

Zhentao Yang, A. Ribas, P. Scumpia, 2020, Cancer discovery.

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Robert Damoiseaux, Antoni Ribas, Mark C Kelley, 2017, Cancer discovery.

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.

N. Sharpless, R. Damoiseaux, R. Lo, 2018, Cancer discovery.

Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma

Zhentao Yang, A. Ribas, R. Lo, 2023, Cancer discovery.